|
|
|
|
|
Highlights from the American Society of Radiation Oncology (ASTRO) Annual Meeting |
|
|
|
|
Special Session - Late-breaking Abstracts
|
|
| GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
|
| Igor Latorzeff, MD
|
| The 2022 ASTRO Annual Meeting was host to a late-breaking abstract session, during which Dr. Igor Latorzeff presented results of the GETUG-AFU 22 trial. Dr. Latorzeff began his presentation by highlighting that PSA persistence post-radical prostatectomy is distinct from biochemical recurrence.
|
|
|
|
|
|
| The Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): A Multicenter, Randomized Phase II Trial
|
| Chad Tang, MD
|
| The 2022 ASTRO Annual Meeting was host to a late-breaking abstract session, during which Dr. Chad Tang presented results of the EXTEND trial: a multicenter, randomized phase II trial evaluating the addition of metastasis-directed therapy (MDT) to intermittent hormone therapy for oligometastatic prostate cancer.
|
|
|
|
|
|
|
Posters - Genitourinary Cancer, Patient Safety, and Nursing
|
|
| The Use of Hyaluronic Acid As Rectal Spacer in Prostate Cancer Patients Undergoing Hypofractionated Radiotherapy: An Australian Experience
|
| Emily Holt
|
| Emily Holt presented on the use of hyaluronic acid as rectal spacer in prostate cancer patients undergoing hypofractionated radiotherapy. The utilization of hypofractionated radiotherapy for prostate cancer can increase patient convenience while also reduce costs. To reduce rectal toxicity, rectal spacers such as hyaluronic acid can be placed in the perirectal space prior to radiotherapy, increasing the distance between the prostate and rectum, allowing room for radiotherapy dose to fall off.
|
|
|
|
|
|
|
|
|
|
|
| A Pilot Study of Salvage HDR Brachytherapy in Recurrent Prostate Cancer: 5 Year Toxicity and Outcomes
|
| Maxime Cloutier, MD
|
| Maxime Cloutier presented 5-year toxicity and outcomes of a pilot study of salvage HDR brachytherapy in recurrent prostate cancer. Cloutier and colleagues designed a single-institution prospective pilot study to evaluate the toxicities and outcomes of HDR brachytherapy as a salvage local therapy.
|
|
|
|
|
|
| Correlation Between Obesity and Treatment Failure Following Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
|
| Dylan Conroy, MD
|
| During this presentation, Dylan Conroy discussed a correlation between obesity and treatment failure following stereotactic body radiation therapy for clinically localized prostate cancer. Cancer control outcomes are significantly worse in obese prostate cancer patients. Over the past decade, stereotactic body radiation therapy has been established as a safe and effective treatment for localized prostate cancer. Conroy and colleagues sought to evaluate oncologic outcomes following stereotactic body radiation therapy for prostate cancer in men based on BMI.
|
|
|
|
|
|
| Toxicity Outcomes at 18 Months for Cs-131 Low-Dose-Rate Prostate Brachytherapy Compared to I-125 and Pd-103
|
| Bradley DePaoli, MD
|
| During this presentation, Bradley DePaoli discussed toxicity outcomes at 18 months for Cs-131 low-dose-rate (LDR) prostate brachytherapy compared to I-125 and Pd-103. LDR prostate brachytherapy is an established component of definitive radiotherapy options for localized prostate cancer. DePaoli and colleagues sought to report the toxicity outcomes up to 18 months after Cs-131 LDR brachytherapy, and compare outcomes to their experience with I-125 and Pd-103.
|
|
|
|
|
|
| Randomized Trial of 18F-fluciclovine vs. 68Ga-PSMA PET/CT Guided Post-Prostatectomy Radiotherapy: Interim Volumetric and Toxicity Analyses
|
| Ashesh Jani, MD
|
| During this presentation, Ashesh Jani discussed interim volumetric and toxicity analyses of a randomized trial of 18F-fluciclovine vs. 68Ga-PSMA PET/CT guided post-prostatectomy radiotherapy. Post-prostatectomy radiotherapy with 18F-fluciclovine (fluciclovine) has demonstrated improved event-free survival compared to conventional imaging (CT and/or MRI) based planning. Jani and colleagues hypothesized that both fluciclovine and PSMA would result in significant changes in radiotherapy volumes and similar acute toxicity.
|
|
|
|
|
|
| Focal MR-Guided High-Dose-Rate Brachytherapy for Localized Prostate Cancer: A Prospective Clinical Trial
|
| Enrique Gutierrez, MD, MHA
|
| During this presentation, Enrique Gutierrez discussed results of a prospective clinical trial assessing focal MR-guided high-dose-rate brachytherapy for localized prostate cancer. Focal therapy has gained traction in the management of localized prostate cancer based on the promise of equivalent oncologic outcomes with minimal toxicity compared to whole gland therapy. Gutierrez and colleagues sought to test the focal therapy hypothesis in a prospective clinical trial of MR-guided HDR for men with localized prostate cancer.
|
|
|
|
|
|
| The Accuracy of Multiparametric MRI in Identification of Intraprostatic Tumor Deposits after Local Prostate Radiation Therapy
|
| Tyler Gutschenritter, MD
|
| During this presentation, Tyler Gutschenritter discussed the accuracy of multiparametric MRI in identification of intraprostatic tumor deposits after local prostate radiation therapy. The objective of this study by Dr. Gutschernritter and colleagues was to determine the accuracy of multiparametric MRI in identification of intraprostatic tumor deposits in prostate cancer patients previously treated with local radiation therapy using a systematic and targeted MR-guided transperineal prostate biopsy technique as a reference to guide and improve clinical workflow processes.
|
|
|
|
|
|
| Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and External Beam Radiation
|
| Claire Hao, MD
|
| During this presentation Claire Hao discussed long-term outcomes of patients on a phase II prospective trial of oligometastatic hormone-sensitive prostate cancer treated with androgen deprivation and external beam radiation. Hao and colleagues reviewed the long-term outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with external beam radiation therapy and ADT on a prospective clinical trial.
|
|
|
|
|
|
| Kinetics and Patterns of PSMA PET Uptake in Prostate Cancer after Radiation Therapy: A Single Center Retrospective Study
|
| Masatoshi Hotta, MD
|
| During this presentation Masatoshi Hotta discussed kinetics and patterns of PSMA PET uptake in prostate cancer after radiation therapy. Recent studies showed the promising results of PSMA PET guided radiotherapy, particularly in oligometastatic disease. However, the kinetics of PSMA PET uptake in prostate cancer lesions after radiation therapy is unknown. The aim of this study presented by Dr. Hotta and colleagues was to assess the patterns of PSMA PET uptake in irradiated lesions using serial PSMA PET/CT scans.
|
|
|
|
|
|
| Toxicity Analysis of Patients with Prostate Cancer Treated with 3D-Conformal Compared to Intensity Modulated Radiotherapy: Secondary Analysis of RTOG 0126 and RTOG 0415
|
| Rebecca F. Krc, DO
|
| During this presentation Rebecca Krc discussed a secondary analysis of RTOG 0126 and RTOG 0415, specifically a toxicity analysis of patients with prostate cancer treated with 3D-conformal radiotherapy (3D-CRT) compared to intensity-modulated radiotherapy (IMRT). The objective of our study was to describe the comparative benefit of IMRT over 3D-CRT for patients undergoing prostate radiation therapy across different radiation therapy dosing and fractionation schemes.
|
|
|
|
|
|
|
